Robotic Partial Nephrectomy London — Retroperitoneal Approach | Mr Denosshan Sri
Robotic surgery · Kidney cancer · London
Robotic Partial Nephrectomy
Kidney-preserving surgery — including the most complex tumours — with the retroperitoneal approach as standard
Robotic-assisted partial nephrectomy (RAPN) removes a kidney tumour while preserving the healthy remainder of the kidney. Mr Sri typically performs this using a retroperitoneal approach — through the back, without entering the abdominal cavity — as his default technique, offering faster recovery and an earlier return to normal life than conventional approaches.
The retroperitoneal approach — why it matters to your recovery
Most robotic kidney surgery is performed through the abdomen (transperitoneal), requiring the bowel to be moved to reach the kidney. Mr Sri approaches the kidney directly from behind — the retroperitoneal route — without entering the abdominal cavity at all. This distinction has meaningful consequences for patients.
Mr Sri introduced this technique to South West London, performs it as his default approach for the majority of cases, and has published on this technique in the Journal of Robotic Surgery. He is one of a small group of European surgeons operating at this volume retroperitoneally.
⚡
Faster return of bowel function
No bowel manipulation means gut function recovers immediately — no bloating, no extended ward stay waiting for bowels to move.
🏠
Home the next morning
Median stay is one night. Patients are mobile on the day of surgery and eating normally within hours of the procedure.
📅
Back to normal activity in 2–3 weeks
Desk work within 2 weeks; physical work within 4–6 weeks. Significantly faster than transperitoneal or open equivalents.
🎯
More direct access to posterior tumours
For tumours on the back or upper pole of the kidney, the retroperitoneal route provides a technically superior operative line.
Mr Sri's personal outcomes — end of 2025
The numbers behind the practice
These figures represent an audit of Mr Sri's personal robotic partial nephrectomy series as of end 2025.
97%
Trifecta rate — negative margins, no major complications, warm ischaemia <25 mins
Published personal series
86%
Trifecta rate including minor complications — a more stringent international benchmark
0.6%
Positive surgical margin rate — among the lowest in published UK series
0%
Conversion to open surgery in personal series to date — entirely minimally invasive practice
0.3%
Conversion to radical nephrectomy where kidney-preservation had been planned
0.3%
Delayed bleeding requiring embolisation — managed without open surgery in all cases
0.3%
Urine leak rate — managed conservatively in all cases
0
Tumour recurrences in Mr Sri's consultant career to date
Case mix & complexity
Treating the full complexity spectrum
Mr Sri accepts tertiary and quaternary referrals for tumours declined for nephron-sparing surgery elsewhere. His case mix reflects one of the most complex partial nephrectomy practices in the UK.
RENAL Score
Complexity
Proportion of series
Score <7
Low
8%
Score 7–9
Intermediate
44%
Score >10
High
48%
Median tumour size 3.2cm (range 1.5–9.0cm). 32% of tumours >4cm. The RENAL Nephrometry Score quantifies tumour complexity based on size, depth, proximity to the collecting system, and location relative to the renal poles.
Second opinions & tertiary referrals
Told your tumour can't be preserved?
A significant proportion of Mr Sri's practice involves patients who have been told elsewhere that kidney-preserving surgery is not possible — and who are found to be suitable candidates on specialist review. A second opinion before proceeding to kidney removal is strongly recommended.
Preserving kidney tissue protects long-term kidney function, reduces cardiovascular risk from chronic kidney disease, and may avoid future dialysis. Referrals are accepted from clinicians and from patients directly, across the UK.
Why saving your kidney matters beyond the operation
Removing a kidney tumour while preserving the rest of the kidney is the standard of care recommended by the European Association of Urology (EAU) for the majority of renal masses where it is technically feasible. The evidence for long-term patient benefit is substantial and independent of cancer control.
Every functioning nephron preserved contributes to glomerular filtration rate (GFR). Chronic kidney disease (CKD) — which results from reduced nephron mass after radical nephrectomy — is independently associated with increased cardiovascular mortality, accelerated hypertension, and the need for dialysis. Partial and radical nephrectomy achieve equivalent cancer control for most kidney tumours: the long-term outcome difference lies in kidney and cardiovascular health over decades following surgery.
Mr Sri's commitment to nephron-sparing surgery extends to the most technically demanding cases — including large, endophytic, and hilar tumours where many surgeons default to radical nephrectomy. His trifecta and pentafecta data confirms this approach can be delivered safely even in high-complexity cases.
EAU guidance
EAU guidelines state that nephron-sparing surgery should be performed for all T1 renal masses where technically feasible, and strongly considered for T2 tumours where expertise allows.
Radical nephrectomy is reserved for cases where partial nephrectomy cannot be performed safely without compromising oncological control.
What happens during robotic retroperitoneal partial nephrectomy
A step-by-step account of what the procedure involves. Mr Sri discusses every step at consultation and pre-operative assessment.
01
General anaesthetic and positioning
You are placed on your side to allow direct posterior access to the kidney. The anaesthetic team monitors you throughout.
02
Port placement — retroperitoneal space
Four or five small keyhole incisions (5–8mm) are made in the back and flank. A balloon creates a working space in the retroperitoneal fat behind the kidney — the bowel cavity is never entered.
03
da Vinci robot docked
The robotic system is connected, providing 3D HD vision and wristed instruments with seven degrees of freedom. Mr Sri operates from a console — the robot does not act autonomously.
04
Hilar control — warm ischaemia begins
The renal artery is temporarily clamped to stop blood flow. Keeping warm ischaemia time below 25 minutes preserves kidney function and is a core trifecta benchmark.
05
Tumour excision with clear margin
The tumour is excised with a measured margin of normal tissue, confirmed intraoperatively. Achieving a negative margin is one of the three core trifecta benchmarks.
06
Renorrhaphy and declamping
The kidney defect is closed in layers with absorbable sutures. The clamp is released and haemostasis confirmed. Blood flow to the kidney resumes immediately.
07
Recovery and discharge
Mobile within hours. Eating on the evening of the procedure. Most patients discharged the following morning.
Recovery timeline
What to expect after surgery
Day of surgery
Surgery and first evening on ward
Mobile within 2–4 hours. Eating and drinking the same evening. Pain managed with oral analgesia — no IV pain pump required for most patients.
Day 1
Discharge
Most patients discharged the morning after surgery. No driving for 2–3 weeks.
Weeks 1–2
Early recovery at home
Light activity and short walks. Avoid lifting more than a kettle. Review at 1 - 2 weeks.
Weeks 2–3
Return to desk work
Most patients in office or desk-based roles return to work at 2–3 weeks. Driving may resume once comfortable and off all analgesia.
Weeks 4–6
Return to physical activity
Exercise, physical work, and moderate lifting. Heavy lifting and contact sports deferred to 4 - 6 weeks.
Weeks 4-6
Outpatient review with Mr Sri
In-person clinic. Kidney function blood test (eGFR). Review of final histology. Surveillance plan discussed.
Peer-reviewed evidence
Publications in robotic partial nephrectomy
Mr Sri has published his personal series data and technical experience in the Journal of Robotic Surgery.
2023
Long-term experience of robotic retroperitoneal partial nephrectomy as the default approach in the management of renal masses: should the paradigm shift?
Robotic-assisted partial nephrectomy (RAPN) and standardisation of outcome reporting: a prospective, observational study on reaching the Trifecta and Pentafecta
I have been told I need my whole kidney removed — is kidney-preserving surgery possible?
Possibly — and always worth clarifying with a specialist before proceeding. Mr Sri operates on tumours in the highest complexity category (RENAL score >10) as 48% of his practice, with a conversion to radical nephrectomy rate of 0.3%. A second opinion before proceeding to kidney removal is strongly recommended. More on kidney cancer and nephron preservation →
How is robotic partial nephrectomy different from open surgery?
Open partial nephrectomy requires a large flank incision (typically 15–20cm) with muscle division, 4–6 nights in hospital, and 6–8 weeks of recovery. Robotic partial nephrectomy uses 3–4 keyhole incisions, with median 1-night stay and return to normal activity in 2–3 weeks in Mr Sri's series.
Will the cancer come back after a partial nephrectomy?
The risk of local recurrence after partial nephrectomy with a clear margin is very low — comparable to radical nephrectomy in appropriately selected cases. Mr Sri has had no tumour recurrences in his consultant career to date. All patients follow a structured surveillance programme with imaging at intervals based on tumour stage and grade.
What is the RENAL Nephrometry Score?
The RENAL Nephrometry Score is a validated scoring system that quantifies kidney tumour complexity across five anatomical dimensions. Scores 4–6 are low complexity, 7–9 intermediate, 10 and above high complexity. 48% of Mr Sri's operated tumours score above 10.
Is robotic partial nephrectomy covered by my health insurance?
Yes — robotic partial nephrectomy for kidney cancer is covered by all major UK private health insurers including BUPA, AXA, Aviva, and Vitality where treatment is clinically indicated. More on insurance and fees →
Patient information resources
Further reading
Established UK urology organisations and peer-reviewed evidence for patients and referring clinicians.
Information on this website is provided for general guidance only and does not replace consultation with a qualified medical professional. Treatment decisions and outcomes vary between individuals and require specialist assessment.
